As previously reported, BofA analyst Tal Liani upgraded Cellebrite to Buy from Neutral with a price target of $12, up from $9, following the company’s “solid” Q4 results, citing improved business momentum into 2024. The firm believes prior headwinds have abated and sees healthy market demand and growth acceleration, driven by new product initiatives, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CLBT:
- Cellebrite Announces Fourth-Quarter 2023 Results
- Cellebrite Revolutionizes Investigative Workflow with Groundbreaking End-to-End Platform to Solve More Cases Faster
- Cellebrite announces Case-to-Closure platform
- Operation Find Them All: Cellebrite Unites Philanthropic Pioneers to Accelerate Investigations of Crimes Against Children
- Cellebrite enters collaboration for investigations of crimes against children